{
  "id": "MISSION-500-152-1771351338439",
  "type": "priorityAction",
  "difficulty": "4-5",
  "topic": "Neuroleptic Malignant Syndrome",
  "text": "The nurse is caring for a 38-year-old male client with a history of schizophrenia and type 2 diabetes mellitus who was admitted from a supported housing facility at 1400 due to acute confusion and stiffness. The nurse has just reviewed the client's new laboratory results and electrocardiogram (ECG) report.",
  "prompt": "Which action is the priority for the nurse to take?",
  "tabs": [
    {
      "id": "ehr",
      "name": "EHR",
      "content": [
        {
          "type": "nursesNote",
          "time": "1400",
          "header": "Emergency Department Nurse's Note",
          "body": "Client brought in by staff from supported housing facility for 'not acting right' over the past 24 hours. Client is diaphoretic, minimally responsive to verbal stimuli, and demonstrates significant generalized 'lead-pipe' muscle rigidity. Staff reports client has had difficulty swallowing and has refused fluids today. Lungs clear to auscultation. Skin is hot and moist to the touch."
        },
        {
          "type": "mar",
          "header": "Medication Administration Record",
          "records": [
            {
              "name": "Olanzapine",
              "dose": "15 mg",
              "route": "PO",
              "frequency": "Daily",
              "timeDue": "1600",
              "notes": "Administer for schizophrenia"
            },
            {
              "name": "Metformin",
              "dose": "1000 mg",
              "route": "PO",
              "frequency": "BID",
              "timeDue": "0800/2000",
              "notes": "Administer for type 2 diabetes"
            },
            {
              "name": "Acetaminophen",
              "dose": "650 mg",
              "route": "PO/PR",
              "frequency": "q4h PRN",
              "timeDue": "PRN",
              "notes": "For fever > 38.0 C"
            }
          ]
        }
      ]
    },
    {
      "id": "vitals",
      "name": "Vital Signs",
      "content": [
        {
          "type": "trendTable",
          "header": "Vital Signs Trend",
          "rows": [
            {
              "label": "Time",
              "values": [
                "1405",
                "1500",
                "1545"
              ]
            },
            {
              "label": "Temperature (°C)",
              "values": [
                "38.8",
                "39.4",
                "40.1"
              ]
            },
            {
              "label": "Heart Rate (/min)",
              "values": [
                "118",
                "126",
                "132"
              ]
            },
            {
              "label": "Blood Pressure (mmHg)",
              "values": [
                "155/90",
                "168/98",
                "140/85"
              ]
            },
            {
              "label": "Respiratory Rate (/min)",
              "values": [
                "24",
                "28",
                "30"
              ]
            },
            {
              "label": "SpO2 (%)",
              "values": [
                "95%",
                "94%",
                "94%"
              ]
            }
          ]
        }
      ]
    },
    {
      "id": "labs",
      "name": "Labs",
      "content": [
        {
          "type": "table",
          "header": "Laboratory Results (STAT)",
          "rows": [
            {
              "label": "Potassium",
              "value": "7.1 mEq/L",
              "range": "3.5-5.0 mEq/L"
            },
            {
              "label": "Creatine Kinase (CK)",
              "value": "28,500 U/L",
              "range": "30-200 U/L"
            },
            {
              "label": "BUN",
              "value": "38 mg/dL",
              "range": "10-20 mg/dL"
            },
            {
              "label": "Creatinine",
              "value": "2.9 mg/dL",
              "range": "0.6-1.2 mg/dL"
            },
            {
              "label": "WBC Count",
              "value": "16.8 x 10³/μL",
              "range": "4.5-11.0 x 10³/μL"
            },
            {
              "label": "Troponin I",
              "value": "<0.04 ng/mL",
              "range": "<0.04 ng/mL"
            }
          ]
        }
      ]
    },
    {
      "id": "diagnostics",
      "name": "Diagnostics",
      "content": [
        {
          "type": "text",
          "header": "12-Lead ECG Interpretation",
          "body": "Sinus tachycardia at 130 bpm. PR and QRS intervals are within normal limits. Prominent, narrow, peaked T waves are noted across precordial leads. No ST segment elevation or depression."
        }
      ]
    }
  ],
  "options": [
    {
      "id": "opt_05",
      "text": "Increase the rate of the maintenance IV fluids.",
      "isCorrect": false,
      "label": "Increase IV Fluids"
    },
    {
      "id": "opt_06",
      "text": "Place the client on a cardiac monitor.",
      "isCorrect": false,
      "label": "Cardiac Monitor"
    },
    {
      "id": "opt_01",
      "text": "Administer the scheduled 1600 dose of olanzapine.",
      "isCorrect": false,
      "label": "Administer Olanzapine"
    },
    {
      "id": "opt_03",
      "text": "Apply a hypothermia blanket and administer PR acetaminophen.",
      "isCorrect": false,
      "label": "Cooling Measures"
    },
    {
      "id": "opt_04",
      "text": "Request a prescription for IV dantrolene.",
      "isCorrect": false,
      "label": "Request Dantrolene"
    },
    {
      "id": "opt_02",
      "text": "Prepare to administer IV calcium gluconate.",
      "isCorrect": true,
      "label": "Calcium Gluconate"
    }
  ],
  "correct": [
    "opt_02"
  ],
  "answerBreakdown": {
    "analyzeCues": "The nurse must synthesize data from all tabs. The client's history (schizophrenia, on olanzapine) combined with the clinical presentation (hyperthermia >40°C, extreme muscle rigidity, altered mental status, autonomic instability with tachycardia and labile BP) strongly indicates Neuroleptic Malignant Syndrome (NMS). The laboratory results confirm this and reveal life-threatening complications: extremely high CK (28,500 U/L) indicates severe rhabdomyolysis, and elevated BUN/Creatinine (38/2.9 mg/dL) shows acute kidney injury (AKI). The most immediate life-threatening finding is the critical hyperkalemia (7.1 mEq/L) resulting from rhabdomyolysis and AKI. This is corroborated by the ECG finding of peaked T waves, a classic sign of hyperkalemic cardiotoxicity, which can rapidly progress to ventricular fibrillation and asystole.",
    "takeAction": "The priority action must address the most immediate threat to life. While NMS requires a multi-faceted approach, the severe hyperkalemia and its cardiac effects are the most urgent problem. Administering IV calcium gluconate is the priority because it directly stabilizes the cardiac membrane, reducing the risk of fatal dysrhythmias. This is a temporizing measure that 'buys time' for other treatments (like insulin/dextrose) to lower the serum potassium level. All other actions are either contraindicated, less urgent, or do not address the immediate threat of cardiac arrest.",
    "optionsRationale": [
      {
        "id": "opt_01",
        "rationale": "Incorrect. This is a critical 'DON'T PROCEED' / 'SAFETY STOP' error. Olanzapine, an antipsychotic, is the presumed causative agent of the NMS. Administering another dose would worsen the syndrome and is absolutely contraindicated. **Pathophysiology:** NMS is thought to be caused by dopamine receptor blockade in the basal ganglia and hypothalamus. This leads to muscle rigidity, hyperthermia, and autonomic instability.",
        "isCorrect": false
      },
      {
        "id": "opt_02",
        "rationale": "Correct. This is the priority nursing action. With a potassium level of 7.1 mEq/L and ECG changes (peaked T waves), the client is at immediate risk of cardiac arrest. IV calcium gluconate is the first-line emergency treatment to stabilize the myocardium and prevent lethal arrhythmias. The nurse should anticipate this order and prepare for administration. **Pathophysiology:** Calcium gluconate does not lower potassium levels but antagonizes the effects of hyperkalemia on the heart by raising the threshold potential, making the myocardium less excitable and reducing the risk of arrhythmias.",
        "isCorrect": true
      },
      {
        "id": "opt_03",
        "rationale": "Incorrect. While treating hyperthermia is a key component of NMS management, it is not the immediate priority over preventing cardiac arrest from hyperkalemia. Cooling measures should be initiated, but only after addressing the cardiotoxic emergency. **Pathophysiology:** Hyperthermia in NMS is due to increased muscle activity and impaired thermoregulation in the hypothalamus.",
        "isCorrect": false
      },
      {
        "id": "opt_04",
        "rationale": "Incorrect. Dantrolene is a muscle relaxant used to treat the rigidity and hypermetabolism of NMS. While it is an indicated treatment for the underlying syndrome, its onset is not as rapid as calcium gluconate, and it does not directly correct the life-threatening hyperkalemia. Stabilizing the heart is the immediate priority. **Pathophysiology:** Dantrolene acts directly on skeletal muscle to reduce muscle contraction by interfering with the release of calcium from the sarcoplasmic reticulum.",
        "isCorrect": false
      },
      {
        "id": "opt_05",
        "rationale": "Incorrect. Aggressive IV hydration is essential for managing rhabdomyolysis and AKI by flushing myoglobin through the kidneys. However, this action will not correct the critically high potassium level quickly enough to prevent a cardiac event. It is a necessary intervention, but secondary to cardiac stabilization. **Pathophysiology:** Rhabdomyolysis releases large amounts of myoglobin into the bloodstream, which can precipitate in the renal tubules, causing kidney damage. IV fluids help to dilute and excrete myoglobin.",
        "isCorrect": false
      },
      {
        "id": "opt_06",
        "rationale": "Incorrect. While the client absolutely must be on a continuous cardiac monitor, this is an assessment and monitoring action, not a therapeutic intervention. Given the critical lab and ECG data, a direct action to prevent clinical deterioration is required. The question asks what the nurse should do, implying an intervention. Preparing a life-saving medication is a higher priority than the act of placing monitor leads, which should have already been done or is done concurrently.",
        "isCorrect": false
      }
    ]
  },
  "cognitiveSkills": [
    "Analyze",
    "Prioritize",
    "Evaluate"
  ],
  "clientNeed": "Physiological Adaptation",
  "priorityConcepts": [
    "Acid-Base Balance",
    "Fluid and Electrolyte Balance",
    "Pharmacology",
    "Clinical Judgment"
  ],
  "sbar": {
    "situation": "38-year-old male with schizophrenia and type 2 diabetes admitted at 1400 for acute confusion and stiffness.",
    "background": "Admitted from supported housing. Diaphoretic, minimally responsive, generalized 'lead-pipe' rigidity, difficulty swallowing, refusing fluids. History of schizophrenia treated with olanzapine.",
    "assessment": "T 38.8-40.1°C, HR 118-132 bpm, BP 155/90-140/85 mmHg, RR 24-30/min, SpO2 95-94%. K+ 7.1 mEq/L, CK 28,500 U/L, BUN 38 mg/dL, Creatinine 2.9 mg/dL, WBC 16.8 x 10³/μL. ECG: Sinus tachycardia 130 bpm, peaked T waves.",
    "recommendation": "Prepare to administer IV calcium gluconate immediately to stabilize the myocardium due to hyperkalemia. Request prescription for IV Dantrolene. Apply hypothermia blanket and administer PR acetaminophen. Place client on cardiac monitor. Increase the rate of maintenance IV fluids. Discontinue Olanzapine."
  },
  "clinicalPearl": "Neuroleptic Malignant Syndrome (NMS) is a life-threatening emergency. Key signs include hyperthermia, muscle rigidity, altered mental status, and autonomic dysfunction. Hyperkalemia is a critical complication that can lead to fatal arrhythmias. Immediate treatment with calcium gluconate is essential to stabilize the myocardium in hyperkalemic patients. Discontinue the offending agent (antipsychotic) immediately. Early recognition and intervention are crucial for improving patient outcomes. Consider NMS in any patient on antipsychotics presenting with unexplained fever, rigidity, and altered mental status.",
  "sentinelStatus": "healed_v2026_v8"
}